Cargando…

Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A

BACKGROUND: BAY 81-8973 is a full-length, unmodified, recombinant human factor VIII (FVIII) for the treatment of hemophilia A. OBJECTIVE: The aim of this study was to compare the pharmacokinetic (PK) profile of BAY 81-8973 with antihemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, Anita, Solms, Alexander, Garmann, Dirk, Katterle, Yvonne, Avramova, Verzhiniya, Simeonov, Stanislav, Lissitchkov, Toshko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563350/ https://www.ncbi.nlm.nih.gov/pubmed/28005225 http://dx.doi.org/10.1007/s40262-016-0492-2

Ejemplares similares

Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting
por: Chen, Rong, et al.
Publicado: (2022)

BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
por: Santoro, Cristina, et al.
Publicado: (2020)

Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
por: Solms, Alexander, et al.
Publicado: (2020)

BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial
por: Ljung, Rolf, et al.
Publicado: (2023)

Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
por: Pocoski, Jennifer, et al.
Publicado: (2016)

Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
por: Shah, Anita, et al.
Publicado: (2019)

Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
por: Solms, Alexander, et al.
Publicado: (2020)

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
por: Lissitchkov, Toshko, et al.
Publicado: (2023)

Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81–8973 compared with other full-length rFVIII products
por: Teare, John M, et al.
Publicado: (2019)

Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach
por: Solms, Alexander, et al.
Publicado: (2019)

Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A
por: Pipe, Steven
Publicado: (2009)

Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial
por: Yang, Renchi, et al.
Publicado: (2019)

Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis
por: O’Hara, Jamie, et al.
Publicado: (2021)

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
por: Mahlangu, Johnny, et al.
Publicado: (2020)

Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81–8973): Final results of the global real‐world study, TAURUS
por: Santoro, Cristina, et al.
Publicado: (2022)

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials
por: Kenet, Gili, et al.
Publicado: (2023)

Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method
por: Berntorp, Erik, et al.
Publicado: (2014)

Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
por: Kavakli, K, et al.
Publicado: (2015)

Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study
por: Lissitchkov, Toshko, et al.
Publicado: (2022)

Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A
por: Rossbach, Hans-Christoph
Publicado: (2010)

Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A
por: Zhao, Yongqiang, et al.
Publicado: (2021)

Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973)
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations
por: Willmann, Stefan, et al.
Publicado: (2018)

A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE)
por: Konkle, Barbara A, et al.
Publicado: (2021)

“Antihemophilic factor is not the only answer for all factor VIII deficiencies.” Case report of odontogenic infection in a patient with hemophilia A, complicated by factor VIII inhibitors, and managed by transfusion of antihemophilic factor and factor VIII inhibitor bypass activity
por: Sudheesh, K. M., et al.
Publicado: (2016)

Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study
por: Windyga, Jerzy, et al.
Publicado: (2020)

Pharmacodynamics, Pharmacokinetics, and Antiviral Activity of BAY 81-8781, a Novel NF-κB Inhibiting Anti-influenza Drug
por: Droebner, Karoline, et al.
Publicado: (2017)

Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)
por: Lissitchkov, Toshko J., et al.
Publicado: (2017)

Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients
por: Abrantes, João A., et al.
Publicado: (2020)

Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients
por: Pabinger, Ingrid, et al.
Publicado: (2023)

Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B
por: Windyga, Jerzy, et al.
Publicado: (2020)

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling
por: Solms, Alexander, et al.
Publicado: (2019)

Focusing in on use of pharmacokinetic profiles in routine hemophilia care
por: Croteau, Stacy E., et al.
Publicado: (2018)

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
por: Preijers, Tim, et al.
Publicado: (2020)

Teicoplanin pharmacokinetics during albumin dialysis
por: Weiler, Stefan, et al.
Publicado: (2010)

Pharmacokinetics of anidulafungin during albumin dialysis
por: Aguilar, Gerardo, et al.
Publicado: (2014)

Joint Bleeding Tendencies in Adult Patients With Hemophilia: It’s Not All Pharmacokinetics
por: Zhou, Jenny Y., et al.
Publicado: (2019)

Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes
por: Croteau, Stacy E., et al.
Publicado: (2020)

Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin
por: Huang, Yue-Jin, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_rtu8iugo1e2vbsmt24ucbjofgf